Scottie Scheffler's Wife Meredith Scheffler Gets Strong Message From PGA Tour Golfer
Scottie Scheffler's Wife Meredith Scheffler Gets Strong Message From PGA Tour Golfer originally appeared on Athlon Sports.
Scottie Scheffler's wife Meredith Scheffler was a fan of the PGA Tour star long before the golfer was rising up leaderboards. Meredith and the couple's son Bennett have become fan favorites given their constant presence at PGA Tour tournaments.
Advertisement
Scottie is now a two-time Masters champion and recently reflected on his anxiety before ultimately winning his first green jacket in 2022. The PGA Tour golfer admitted to "crying a lot" ahead of the final round, but it was Meredith who was a calming presence.
"I've worked my whole life to have a chance to win the Masters, and I was a bit overwhelmed," Scottie told Rolex during a May 19, interview. "I remember crying a lot. Just because I was able to sit there with my wife. She's my biggest supporter. She knows me better than anybody."
Scottie Scheffler poses for a photo with his wife Meredith and son Bennett after winning the PGA Championship golf tournament at Quail Hollow.Jim Dedmon-Imagn Images
"She saw me go from being a fairly anonymous player on the (PGA Tour) to being No. 1 in the world. And going to have a chance to win my first major," Scottie continued.
"She kind of reminded me why I go out to play. If I lost that day, she loves me the same. It's the same for my family, and I get emotional because I really believe that."
Advertisement
The high school sweethearts have been married since Dec. 4, 2020. Their longtime relationship dates back to their time at Highland Park High School in Dallas, Texas.
Now that Scottie has won three majors, hopefully the anxiety has subsided before marquee rounds. Regardless, Scottie's relationship with his wife Meredith while raising their son Bennett continues to be a major part of his success.
Related: Scottie Scheffler, Wife Meredith Celebrate Family Milestone With Seven-Word Message
This story was originally reported by Athlon Sports on Jun 1, 2025, where it first appeared.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
33 minutes ago
- Wall Street Journal
Stocks to Watch on Tuesday: Paramount, TSMC, Dollar General
🔎 Paramount (PARA): The entertainment conglomerate, which is in negotiations to settle an election-interference lawsuit by President Trump, nominated three new directors to its board. The CBS owner scheduled its shareholder meeting for July 2. 🔎 TSMC (TSM): The global chipmaker faces limited impact from tariffs, as levies are typically borne by importers, Chief Executive C.C. Wei said at a shareholder meeting. He guided for revenue and earnings to hit new highs this year. ↗️ Wolfspeed (WOLF): The semiconductor company rose in brisk trading off-hours. The stock has been volatile in recent weeks. The Wall Street Journal reported in late May that Wolfspeed was preparing to file for bankruptcy.
New York Times
34 minutes ago
- New York Times
Mets' Paul Blackburn returns looking better than ever in win over Dodgers
For the final time Monday night, New York Mets starting pitcher Paul Blackburn pulled from his scouting report on Shohei Ohtani, memories of first-hand experience from their shared time in the same division. Judging from how Blackburn pitched to Ohtani, it's likely the prep work strongly suggested to locate cutters up and in, offer changeups low and out of the strike zone. For the third time using that formula, Blackburn retired Ohtani, who hit a routine grounder with two runners on base to end the fifth inning. Advertisement Blackburn is typically reserved and soft-spoken. But after recording the final out of the fifth inning, which concluded his outing, he slapped his glove in triumph. While walking to the dugout with his head down, he briefly shouted to himself. Given Blackburn's path, some show of emotion, even for a 31-year-old veteran, seemed only natural. After waiting nine months since his last appearance in the major leagues, Blackburn blanked the Los Angeles Dodgers for five innings in the Mets' 4-3 win. Blackburn last pitched in a major-league game on Aug. 23, 2024. In that game, he was struck by a comebacker and landed on the injured list. From there, he missed the rest of the 2024 season due to a spinal leak in his back. He did not know if he would pitch again. After surgery, however, he entered spring training as a healthy player. Then came what he said was the worst part: right knee inflammation in late March resulting in a trip to the injured list, where he stayed until Monday (along the way, he also got sick, delaying an earlier return). 'For him to be out there after so much time that he missed, unbelievable job there,' Mets manager Carlos Mendoza said. Welcome back, Blackburn!@moomooApp | #LGM — New York Mets (@Mets) June 3, 2025 In line with the overall upswing of the Mets' pitching staff this season, Blackburn returned looking better than before. Despite being sidelined, Blackburn gained movement on all of his pitches. Also, he pitched smarter, and not just against Ohtani, who struck out twice against him. Blackburn leaned on his cutter, curveball and changeup. He did not throw a single four-seam fastball, a pitch he used to throw about 20 percent of the time. He didn't throw a four-seamer in his final rehab appearance, either. That is not a coincidence. The thinking for Blackburn and the Mets is, why should he mess with throwing a four-seamer, a pitch batters slugged .694 in plate appearances that ended against it last season, when his cutter is good? Advertisement Under pitching coach Jeremy Hefner's guidance, the Mets' pitching staff owns the best ERA (2.88) in MLB. They are rolling to such an extent that they didn't merely survive by plugging in a sixth starter making his season debut against the defending World Series champion — they succeeded. Blackburn, who attacked the strike zone and pitched efficiently, allowed just three hits and a walk with three strikeouts. The Mets called on Blackburn to give their starters, notably Kodai Senga, an extra day of rest while in a stretch of 10 straight games. His stay in the rotation is not expected to last longer than Monday. He is likely to slide into a long relief role. 'There's a good chance he goes back to the bullpen for now, and we'll go from there,' Mendoza said. Even after a strong first start back, the Mets don't need Blackburn in the rotation. New York Mets president of baseball operations David Stearns' pitching plan is working. Stearns went into last offseason with a preference on adding to his starting pitching depth. He steered away from long-term contracts, didn't last long in the most expensive aisle for pitchers during free agency. The Mets (38-22) have played all season without Sean Manaea and Frankie Montas, their two top pitching acquisitions from the winter. Montas, who has made two rehab starts, may return by the end of June and Manaea is behind him after just recently starting to face batters. Blackburn said he is willing and ready to pitch in whatever role the club needs. 'I'm not blind to the guys who are coming off the IL here soon,' Blackburn said. The downside of relying on depth in the way the Mets do is they will likely need to make roster moves for their bullpen. With six starters, even temporarily, the bullpen is down a pitcher until Blackburn is rested enough to appear in relief. After a 10-inning game on Monday, it would likely be challenging to get through the next six games before the next off day without fresh arms. The Mets are proving that the upside, at least right now, is hard to argue against. (Jason Parkhurst/Imagn Images)
Medscape
36 minutes ago
- Medscape
Systemic Psoriasis Therapy Linked to Less Dementia
SAN DIEGO — While psoriasis is linked to higher rates of dementia, a new study suggested that older patients with psoriasis on systemic treatments may have a much lower risk than those not treated systemically. In fact, the research hints — but doesn't prove — that the medications could lower the dementia risk even below that of the general population. The study, which retrospectively evaluated US medical records of people aged 65-95 years from 2004 to 2024, found that patients with psoriasis on systemic therapies (n = 14,679) had a lower risk of developing dementia than those not on systemic treatment (n = 39,601) and lower than a matched general population group (5.77 million). The adjusted odds ratios (aORs) for the treated psoriasis group vs the untreated group were 0.49 (0.39-0.61) for Alzheimer's disease, 0.65 (0.51-0.83) for vascular dementia, and 0.60 (0.53-0.68) for nonvascular dementia. For the treated group vs the matched general population, the aORs were 0.69 (0.54-0.86), 0.85 (0.65-1.10), and 0.85 (0.75-0.97), respectively. The findings, presented at the Society for Investigative Dermatology (SID) 2025 Annual Meeting, are too preliminary to affect clinical practice. But the study does add to 'a growing body of evidence linking chronic inflammation to neurodegeneration,' study lead author Madison Olexson, a dermatology research fellow at Eastern Virginia Medical School, Norfolk, Virginia, told Medscape Medical News . 'It reinforces [how] treating systemic diseases like psoriasis may not only improve cutaneous symptoms but may have extra-cutaneous benefits as well,' she said. Sparse Data on Systemic Treatments and Psoriasis Several international reports have linked psoriasis with dementia, including a 2019 study that found an elevated risk associated with the skin disease and vascular dementia (hazard ratio [HR], 1.73; 95% CI, 1.21-2.47) and a 2023 study that identified an increased risk for dementia (HR, 1.24; 95% CI, 1.14-1.35). Also, a 2019 study linked dementia to a higher risk for psoriasis (OR, 1.46). Other autoimmune disorders such as rheumatoid arthritis and inflammatory bowel disease have also been linked to higher incidence and risk for cognitive impairment and dementia, Olexson said. 'This is believed to be linked to systemic inflammation and the sustained activity of proinflammatory cytokines such as [tumor necrosis factor] TNF alpha and [interleukin 17] IL-17, which can affect the brain and potentially lead to neurodegeneration. However, the exact mechanisms remain unclear.' She added that 'it's still a mystery whether psoriasis alone drives the development of dementia or if the increased likelihood is due to shared comorbidities or overlapping inflammatory pathways. Furthermore, we don't yet fully understand whether treatments provide direct cognitive protection or how long treatment needs to continue for maximal benefit.' Biologics and Non-Biologics Both Linked to Benefit The researchers launched the new study 'to address the limited and inconsistent data on whether psoriasis associates with dementia outcomes and systemic treatments for psoriasis could influence the likelihood of developing dementia,' Olexson said. The study retrospectively tracked patients via the TriNetX research network database. Before propensity score matching, the mean age was 66.6 ± 8.9 years for non-treated patients and 67.8 ± 9.0 years for the general population. Respectively, the groups were 42.8% and 51.7% women and 65.9% and 72.6% White. Data for the treated psoriasis group were not provided, but Olexson said their characteristics were similar. The study included both biologic medications, which target specific immune pathways, and non-biologic systemic treatments. Patients were treated for a median of 4 years (for both). The biologics were adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, ustekinumab, guselkumab, tildrakizumab, risankizumab, secukinumab, ixekizumab, and brodalumab. The non-biologic treatments were methotrexate, apremilast, acitretin, and ultraviolet phototherapy. Both drug classes were linked to lower risks for dementia at roughly the same rates, but it was not clear if specific medications may have greater effects. Less Inflammation May Protect Against Dementia The adjusted incidence rates of Alzheimer's disease were 1.9% vs 1.2% in the non-psoriasis group vs the treated psoriasis group. For vascular dementia, the rates were 1.2% vs 0.74%, respectively. For nonvascular dementia, they were 5.4% vs 3.7%, respectively. For untreated patients with psoriasis vs treated patients with psoriasis, the adjusted incident rates were 1.7% and 0.84% for Alzheimer's disease, 1.1% and 0.72% for vascular dementia, and 5.1% and 3.1% for nonvascular dementia, respectively, which Olexson reported were statistically significant differences. 'Systemic therapies likely reduce neuroinflammation by suppressing inflammatory cytokines like TNF alpha and IL-17, both of which have been implicated in neurodegenerative processes,' Olexson said. 'These cytokines can disrupt the blood-brain barrier, promote amyloid beta accumulation, and impair neuronal function. By modulating this inflammatory cascade, systemic treatments may protect against or slow the onset of dementia.' Findings Are 'Intriguing' but Not Definitive Asked to comment on the results, Steven R. Feldman, MD, PhD, professor of dermatology, Wake Forest University, Winston-Salem, North Carolina, who was not involved in the study, noted that while the findings are 'intriguing,' they come with caveats because of the observational study design. 'If patients with dementia aren't bothered by their psoriasis or aren't given biologics for that or some other reason, getting a biologic might be associated with less dementia,' he said in an interview. 'It may be that having or not having dementia determines to some degree who gets a biologic, not that taking a biologic determines who gets dementia.' Olexson agreed that the observational design has limitations. While cohorts were matched by demographics, body mass index, and several comorbidities, she said other factors such as disease severity, socioeconomic status, and access to care could play a role in the findings. What's next? Moving forward, Olexson said, 'We have plans to conduct prospective studies related to psoriasis and cognitive health at our institution.'
